Fibrex' strong data on reperfusion injury drug

Fibrex Medical, a biopharmaceutical company based in Vienna, Austria. and focusing on cardiovascular and inflammatory diseases, presented positive Phase II results for FX06, a peptide for the treatment of reperfusion injury at the European Society of Cardiology congress in Munich, Germany.

The Phase II clinical trial of FX06 in 234 patients with acute myocardial infarcts was completed in March, with data indicating a statistically-significant reduction in myocardial necrosis compared to placebo following intravenous application of the agent during reperfusion treatment. FX06 is a peptide that binds to vascular endothelial cadherin, thereby inhibiting tissue inflammation and injury as well as preserving endothelial barrier function. These effects are deemed to be important for the prevention of the paradoxical additional damage to the heart muscle known as reperfusion injury.

Fibrex says it is now planning a development program to bring the product to registration and will seek a licensing partner. The program will be discussed with regulatory agencies in the USA and Europe later this year.